Table 3.
Effect of liraglutide versus placebo on anthropometric and biochemical variables
| Treatment effect | Difference | 95 % CI | p value | ||
|---|---|---|---|---|---|
| Liraglutide | Placebo | ||||
| Weight, kg | −4.17 (3.49) | −0.98 (2.62) | −3.18 (4.31) | −4.79 to −1.57 | <0.001 |
| Waist, cm | −2.80 (4.11) | −0.57 (2.52) | −2.22 (4.89) | −4.16 to −0.29 | 0.026 |
| BMI, kg/m2 | −1.35 (1.10) | −0.31 (0.85) | −1.04 (1.34) | −1.54 to −0.54 | <0.001 |
| Systolic blood pressure, mmHg | −8.10 (17.27) | −3.17 (16.07) | −4.93 (23.68) | −13.78 to 3.91 | 0.263 |
| Diastolic blood pressure, mmHg | −3.13 (12.11) | −3.83 (8.75) | 0.70 (17.06) | −5.67 to 7.07 | 0.826 |
| HbA1C, % | −0.42 (0.34) | −0.04 (0.43) | −0.37 (0.54) | −0.57 to −0.17 | <0.001 |
| LDL-cholesterol, mmol/L | −0.25 (0.72) | −0.17 (0.63) | −0.08 (0.96) | −0.47 to 0.30 | 0.657 |
| HOMA IR, pmol/L | −1.35 (3.18) | −0.57 (2.41) | −0.78 (3.24) | −2.01 to 0.45 | 0.336 |
| Fasting plasma insulin, pmol/L | −11.73 (57.54) | −1.69 (43.79) | −10.04 (68.27) | −36.01 to 15.93 | 0.469 |
| Fasting blood glucose, mmol/L | −0.99 (1.11) | −0.62 (0.96) | −0.36 (1.06) | −0.76 to 0.03 | 0.125 |
Data are expressed as the mean (SD)
BMI body mass index, HbA1C glycated hemoglobin, LDL low-density lipoprotein, HOMA IR homeostasis model analysis of insulin resistance